The aim of the project is non-clinical and clinical confirmation of the efficacy and safety of the compound CPL116 — an innovative JAK/ROCK kinase inhibitor developed at Celon Pharma – in inhalation indices: asthma, chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF). Chronic respiratory diseases with inflammatory and fibrosis affect millions of people worldwide. The activity of the JAK/ROCK pathway plays a major role in their etiology, but even though molecular targets have been identified, this pharmaceutical area is still unmet. CPL116, developed by the Applicant, is a highly active JAK1/3 kinase inhibitor, as demonstrated in in vitro studies. Inhibition of the JAK pathway leads to inhibition of inflammation and improved lung function. Additional blocking of ROCK kinases allows for simultaneous inhibition of fibrosis processes, which may be crucial in the therapy of IPF and progressive pulmonary fibrosis changes observed in COVID-19 disease. Number_reference_aid_programme: SA.41471(2015/X) Purpose of public aid: art: 25 EC Regulation No 651/2014 of 17 June 2014 declaring certain categories of aid compatible with the internal market in the application of Articles 107 and 108 of the Treaty (OJ L 119, p. That’s it. EU L 187/1 of 26.06.2014).